TY - JOUR T1 - Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension JF - European Respiratory Journal JO - Eur Respir J SP - 92 LP - 98 DO - 10.1183/09031936.00094808 VL - 33 IS - 1 AU - B. Degano AU - A. Yaïci AU - J. Le Pavec AU - L. Savale AU - X. Jaïs AU - B. Camara AU - M. Humbert AU - G. Simonneau AU - O. Sitbon Y1 - 2009/01/01 UR - http://erj.ersjournals.com/content/33/1/92.abstract N2 - Bosentan has proven 4-month efficacy in patients with HIV-associated pulmonary arterial hypertension (PAH-HIV). Herein, the long-term outcome of unselected PAH-HIV patients treated with first-line bosentan is described. Data for 59 consecutive World Health Organization (WHO) functional class II–IV PAH-HIV patients treated with first-line bosentan between May 2002 and July 2007 were analysed. HIV status, 6-min walk distance and haemodynamics were assessed at baseline, after 4 months and every 6–12 months thereafter. After 4 months, 6-min walk distance increased from 358±98 to 435±89 m and pulmonary vascular resistance decreased from 737±328 to 476±302 dyn·s·cm−5. At the final evaluation (29±15 months), 6-min walk distance remained stable and pulmonary vascular resistance decreased further to 444±356 dyn·s·cm−5. Haemodynamics normalised in 10 patients. At their last evaluation, these 10 patients were in WHO functional class I, with a 6-min walk distance of 532±52 m. Overall survival estimates were 93, 86 and 66% at 1, 2 and 3 yrs, respectively. Bosentan was safe when combined with highly active antiretroviral therapy, with no negative impact on HIV infection control. The present data confirm the long-term benefits of bosentan therapy in HIV-associated pulmonary arterial hypertension patients with improvements in symptoms, 6-min walk distance and haemodynamics, and with favourable overall survival. ER -